Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Fill-Finish Pharmaceutical Contract Manufacturing Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The industry report delineates the escalation of the market from $10.02 billion in 2022 to a projected $10.96 billion in 2023, marking a CAGR of 9.40%. This surge is attributable to several factors, including the increasing demand for pharmaceutical products, proactive R&D investments, and the ever-evolving landscape of medical requirements. Despite the challenges posed by the recent global events, the fill-finish pharmaceutical contract manufacturing market is poised to reach new heights, estimated at $15.44 billion by 2027, with a CAGR of 8.94%.
The global pharmaceutical industry is observing a robust expansion within the fill-finish contract manufacturing sector, as revealed by a freshly compiled market research publication. The comprehensive report meticulously dissects current trends, future projections, and technological advancements fueling the demand for such specialized services.
This insightful analysis is expected to serve as an indispensable resource for stakeholders within the fill-finish pharmaceutical contract manufacturing market. It sheds light on the complexities of this niche yet critical segment of the pharmaceutical manufacturing pipeline, which includes prefilled syringes, vials, cartridges, and other deliverables crucial to modern healthcare provision.
Highlighted within the report is the remarkable growth anticipated in the Asia-Pacific region, predicted to be the fastest-growing amongst its global counterparts. A key trend identified is the adoption of groundbreaking technologies by industry players, aiming to refine product quality and comply with stringent regulatory standards. For instance, Steriline s.r.l.’s introduction of robotic technologies tailored for small-batch aseptic filling exemplifies this strategic adoption of innovation.
Technological Advancements Spearhead Market Growth
Industries related to fill-finish pharmaceutical contract manufacturing are embracing forward-thinking technologies to stay competitive in a dynamic market. Such advancements are not only pivotal in adhering to regulatory mandates but also ensure higher safety standards, precision in dosing, and consistency in product quality.
Strategic Acquisitions Reshaping the Competitive Landscape
The strategic moves, such as PCI Pharma Services' acquisition of Lyophilization Services of New England Inc. (LSNE), significantly enhance capabilities and service portfolios, illustrating the market's competitive nature.
Key Market Segments and Regional Insights
The report provides an extensive segmentation of the market, highlighting specific areas that have witnessed substantial growth. It covers different product types like prefilled syringes and vials among others and services for both large molecules and small molecules.
- Analysis of regional market strengths, with a keen focus on North America's prevalent dominance and Asia-Pacific's rapid growth.
- Insight into various countries’ market performance including Australia, Brazil, China, Germany, India, Japan, and the USA.
- Examination of market demands and how increasing pharmaceutical needs are propelling the industry forward.
This research accentuates the competitive landscape, showcasing prominent players such as AbbVie Inc., Thermo Fisher Scientific Inc., Catalent Inc., and many others who are redefining the fill-finish pharmaceutical contract manufacturing industry.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $10.96 billion |
| Forecasted Market Value (USD) by 2027 | $15.44 billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes
- AbbVie Inc.
- Novartis AG
- Thermo Fisher Scientific Inc.
- Fresenius Kabi
- Abbott Laboratories
- Eurofins Scientific SE
- Lonza Group Ltd.
- Catalent Inc.
- Sun Pharmaceutical Industries Limited
- West Pharmaceutical Services Inc.
- Patheon
- Samsung Biologics Co.Ltd.
- WuXi Biologics
- Piramal Pharma Solutions
- Pfizer CentreOne
- Recipharm AB
- Emergent BioSolutions Inc.
- Boehringer Ingelheim BioXcellence
- Corden Pharma GmbH
- Aenova Group
- Baxter BioPharma Solutions
- FUJIFILM Diosynth Biotechnologies
- AGC Biologics
- Rentschler Biopharma SE
- Recro Pharma Inc.
- Cobra Biologics Limited
- Grand River Aseptic Manufacturing (GRAM)
- MabPlex International Ltd.
- Cerbios-Pharma SA
- Symbiosis Pharmaceutical Services Limited.
For more information about this report visit https://www.researchandmarkets.com/r/1v3vqf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
